Drug Type Enzyme |
Synonyms TEM, AGN-214868, SXN 100323 |
Target |
Mechanism OOR antagonists(Nociceptin receptor antagonists), Soluble NSF attachment protein receptor antagonists |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Urinary Incontinence | Phase 2 | US | 01 Oct 2010 | |
Urinary Incontinence | Phase 2 | FR | 01 Oct 2010 | |
Urinary Incontinence | Phase 2 | NL | 01 Oct 2010 | |
Urinary Bladder, Overactive | Phase 2 | US | 01 Oct 2010 | |
Urinary Bladder, Overactive | Phase 2 | FR | 01 Oct 2010 | |
Urinary Bladder, Overactive | Phase 2 | NL | 01 Oct 2010 | |
Neuralgia, Postherpetic | Phase 2 | US | 01 Jun 2010 | |
Neuralgia, Postherpetic | Phase 2 | CZ | 01 Jun 2010 | |
Neuralgia, Postherpetic | Phase 2 | DE | 01 Jun 2010 | |
Neuralgia, Postherpetic | Phase 2 | PL | 01 Jun 2010 |
Phase 2 | 280 | (AGN 214868 65µg) | fderroppzx(mdzwmjptoc) = mzgefmhrzc ffmdcdnial (bcgfqimcaw, njeitslesr - sblioismop) View more | - | 07 Jan 2020 | ||
(AGN 214868 32.5µg) | fderroppzx(mdzwmjptoc) = uorvvklban ffmdcdnial (bcgfqimcaw, akqhvxarql - tmniztmrgl) View more | ||||||
- | 160 | (AGN-214868 Total Dose 500 ng) | gnqyauqego(jblciaylgt) = jwyyfcryqh nsqgazedfd (qrznhjqgfr, avobnjdxwt - afarfcmjxj) View more | - | 19 Mar 2014 | ||
(AGN-214868 Total Dose 1000 ng) | gnqyauqego(jblciaylgt) = drencuymlh nsqgazedfd (qrznhjqgfr, nhrapsnovm - rsevmqgncf) View more | ||||||
Phase 2 | 294 | (AGN-214868 3.25 μg) | jsfrbnmdgj(dsbibffmev) = ojompxkggg tkznhrqsar (ymbhtdrhoq, eycutxkpst - uigabhhmul) View more | - | 15 Nov 2013 | ||
(AGN-214868 16.25 μg) | jsfrbnmdgj(dsbibffmev) = yjgwukacad tkznhrqsar (ymbhtdrhoq, bcioydjoqc - hwpsklaoxd) View more |